Polen Capital Management
PTGX icon

Polen Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Polen Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Sell
22,651
-1,686
-7% -$176K 0.02% 103
2026
Q1 		$2.57M Buy
24,337
+3,988
+20% +$353K 0.02% 86
2025
Q4 		$1.78M Buy
20,349
+24
+0.1% +$1.96K 0.01% 102
2025
Q3 		$1.35M Buy
20,325
+4,326
+27% +$246K ﹤0.01% 122
2025
Q2 		$884K Buy
+15,999
New +$768K ﹤0.01% 152

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Polen Capital Management's PTGX Position: Q2 2026 in Review

Polen Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 6.9% in Q2 2026, selling an estimated $176K and leaving 22,651 shares worth $2.78M. The position accounts for 0.02% of the portfolio, ranked #103.

Polen Capital Management first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Polen Capital Management held 22,651 shares of Protagonist Therapeutics worth $2.78M as of Q2 2026.
  • Polen Capital Management sold 1,686 Protagonist Therapeutics shares in Q2 2026, an estimated $176K.
  • Protagonist Therapeutics made up 0.02% of Polen Capital Management's portfolio in Q2 2026, its #103 holding.
  • Polen Capital Management first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Polen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.